Infectious toxicity using alemtuzumab.
Nosari
Annamaria
A
Montillo
Marco
M
Morra
Enrica
E
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000074323:Alemtuzumab; D019072:Antibiotic Prophylaxis; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000494:pharmacology; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D016026:Bone Marrow Transplantation; D000074301:CD52 Antigen; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D004198:Disease Susceptibility; D000077595:Famciclovir; D015774:Ganciclovir / Q000627:therapeutic use; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D015994:Incidence; D007239:Infections / Q000209:etiology*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D000069283:Rituximab; D019172:Transplantation Conditioning; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014766:Viremia / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D015075:2-Aminopurine; D000069283:Rituximab; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D015774:Ganciclovir; D000077595:Famciclovir